Advanced Medical Solutions Group (LSE:AMS) Total Liabilities : £45.0 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Advanced Medical Solutions Group Total Liabilities?

Advanced Medical Solutions Group's Total Liabilities for the quarter that ended in Dec. 2023 was £45.0 Mil.

Advanced Medical Solutions Group's quarterly Total Liabilities increased from Dec. 2022 (£44.47 Mil) to Jun. 2023 (£48.82 Mil) but then declined from Jun. 2023 (£48.82 Mil) to Dec. 2023 (£44.97 Mil).

Advanced Medical Solutions Group's annual Total Liabilities increased from Dec. 2021 (£36.83 Mil) to Dec. 2022 (£44.47 Mil) and increased from Dec. 2022 (£44.47 Mil) to Dec. 2023 (£44.97 Mil).

Advanced Medical Solutions Group Total Liabilities Historical Data

The historical data trend for Advanced Medical Solutions Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Medical Solutions Group Total Liabilities Chart

Advanced Medical Solutions Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

35.75

36.34

36.83

44.47

44.97

Advanced Medical Solutions Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															36.83	43.55	44.47	48.82	44.97

Advanced Medical Solutions Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Advanced Medical Solutions Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	21.583	+	(7.973	+	15.413
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	45.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	289.171	-	244.202
	=	45.0

Advanced Medical Solutions Group's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	21.583	+	(7.973	+	15.413
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	45.0

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	289.171	-	244.202
	=	45.0

Advanced Medical Solutions Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Advanced Medical Solutions Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Medical Solutions Group (LSE:AMS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (LSE:AMS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AMS.GB:UK AQA:Germany

Address

Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT

Website

https://www.admedsol.com

U.K.-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.